Key result
Small peptide IRW reduces blood pressure via ACE2 axis upregulation in hypertensive rat models.
Why the study?
The mechanisms of action, bioavailability, metabolism, and potential therapeutic roles of the ACE2 activating peptide IRW require further investigation.
May inform ACE2-targeted peptide development; leaves open translation to human hypertension therapy.
digestion and quantitative structure and activity relationship prediction in 2011. Oral administration of IRW to spontaneously hypertensive rats (SHRs) can significantly reduce blood pressure, via upregulation of ACE2, but not through the inhibition of ACE. ACE2 converts Ang II into Ang (1-7), thus lowering blood pressure via Mas receptor (MasR); coinfusion of Mas receptor antagonist A779 and IRW in SHRs abolished blood pressure-lowering effect of IRW, supporting a key role of ACE2/Ang (1-7)/MasR axis. Our ongoing study further established new roles of IRW as an antioxidant, an anti-inflammatory agent, an insulin sensitizer, and a bone cell anabolic. Future studies are warranted to understand the unique structure features of this peptide, its mechanisms of action at various targets, its bioavailability and metabolism, and its possible roles toward COVID-19.
No takes yet. Share an insight, caveat, or question.
Jianping Wu (2020) conducted a review in Hypertension (in animal models). Ile-Arg-Trp (IRW) was evaluated on Blood pressure. Oral administration of the small peptide IRW significantly reduced blood pressure in spontaneously hypertensive rats via upregulation of ACE2 and the ACE2/Ang (1-7)/MasR axis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: